'UrGenT' and 'CardioGenix': The early development of two German Biotech ventures, and the impact of venture capitalists and the financial markets on them: European Case Study no 4/5, Gate 2 Growth project, European Commission, 2004

Robert Cressy; S Remer

'UrGenT' and 'CardioGenix': The early development of two German Biotech ventures, and the impact of venture capitalists and the financial markets on them: European Case Study no 4/5, Gate 2 Growth project, European Commission, 2004

Robert Cressy, S Remer

Research output: Other contribution

Original language	English
Type	Other Contribution
Publication status	Published - 1 Jan 2004

Cite this

@misc{fab8e73825ec47769af1741d4243bd19,

title = "'UrGenT' and 'CardioGenix': The early development of two German Biotech ventures, and the impact of venture capitalists and the financial markets on them: European Case Study no 4/5, Gate 2 Growth project, European Commission, 2004",

author = "Robert Cressy and S Remer",

year = "2004",

month = jan,

day = "1",

language = "English",

type = "Other",

}